Just trading and things
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Realistically should be $6+
Avinger Inc says that with the recent FDA approval, it is planning to immediately launch its two Pantheris Lumivascular devices in the U.S.
$AVGR BUY ALERT .. BUY BUY BUY 4 BAGGER FDA APPROVED
$AVGR BUY ALERT .. BUY BUY BUY 4 BAGGER FDA APPROVED
1 more week!
Should see an EOD breakout IMO
Let's play spot the bear xD
Wow 0_0 Flipped this quick from .19 to .26 what happened!?
8 days!
$XTNT 6.10 BREAKING FDA APPROVAL! Short interest 68%
Xtant Medical Receives FDA 510(K) Clearance for InTice(TM)-C Porous Titanium Cervical Interbody System ACCESSWIRE ACCESSWIRE•May 21, 2018 BELGRADE, MT / ACCESSWIRE / May 23, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice™-C Porous Titanium Cervical Interbody System.
InTice-C is designed using OsteoSync Ti, a best-in-class, cost-effective, highly porous titanium scaffold material for improved implant fixation. The material more closely resembles the bioscaffold of cancellous bone, and further combines Xtant Medical's hardware and biologic portfolios. In addition to InTice-C serving as a bioactive scaffold, it is also cleared for use with Xtant's proprietary allograft lines, including OsteoSponge®, 3Demin® Cortical Fibers, and OsteoVive™ viable cell allograft.
"InTice-C represents Xtant's latest addition to our spinal implant portfolio and is our first spinal implant to be engineered using a best-in-class porous titanium material," stated Dr. Gregory Juda, Chief Scientific Officer and General Manager of Xtant Medical. "The porous architecture of the titanium was designed to improve implant fixation, both prior and post fusion. We expect a positive reception of this technology from our surgeon customers in the cervical spine market."
The InTice-C Is designed to provide cervical intervertebral body fusion options for each patient's varied anatomy. It is offered in multiple footprint, height and endplate options. The commercial pure titanium structure offers continuous pore interconnectivity from the top to the bottom as well as from the outer perimeter to the large central graft cavity of the implant. This optimizes vascularization to the fusion site allowing the implant to be a participant in the fusion process. The implant utilizes machined endplate structures in conjunction with the inherent texture of the porous titanium to provide migration resistance. The implant is offered in individual sterile packages. InTice-C was developed in collaboration with Sites Medical.
InTice-C will help the Company further penetrate the $285 million dollar cervical spine market. Xtant's other cervical interbody options include Calix®-C, Calix-C PC, Atrix-C®, and Irix®-C, which offer PEEK, PEEK with a plasma-coated titanium, a structural biologic solution, and a standalone cervical option, respectively.
About Xtant Medical
Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
$XTNT 6.10 BREAKING FDA APPROVAL! Short interest 68%
Xtant Medical Receives FDA 510(K) Clearance for InTice(TM)-C Porous Titanium Cervical Interbody System ACCESSWIRE ACCESSWIRE•May 21, 2018 BELGRADE, MT / ACCESSWIRE / May 23, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice™-C Porous Titanium Cervical Interbody System.
InTice-C is designed using OsteoSync Ti, a best-in-class, cost-effective, highly porous titanium scaffold material for improved implant fixation. The material more closely resembles the bioscaffold of cancellous bone, and further combines Xtant Medical's hardware and biologic portfolios. In addition to InTice-C serving as a bioactive scaffold, it is also cleared for use with Xtant's proprietary allograft lines, including OsteoSponge®, 3Demin® Cortical Fibers, and OsteoVive™ viable cell allograft.
"InTice-C represents Xtant's latest addition to our spinal implant portfolio and is our first spinal implant to be engineered using a best-in-class porous titanium material," stated Dr. Gregory Juda, Chief Scientific Officer and General Manager of Xtant Medical. "The porous architecture of the titanium was designed to improve implant fixation, both prior and post fusion. We expect a positive reception of this technology from our surgeon customers in the cervical spine market."
The InTice-C Is designed to provide cervical intervertebral body fusion options for each patient's varied anatomy. It is offered in multiple footprint, height and endplate options. The commercial pure titanium structure offers continuous pore interconnectivity from the top to the bottom as well as from the outer perimeter to the large central graft cavity of the implant. This optimizes vascularization to the fusion site allowing the implant to be a participant in the fusion process. The implant utilizes machined endplate structures in conjunction with the inherent texture of the porous titanium to provide migration resistance. The implant is offered in individual sterile packages. InTice-C was developed in collaboration with Sites Medical.
InTice-C will help the Company further penetrate the $285 million dollar cervical spine market. Xtant's other cervical interbody options include Calix®-C, Calix-C PC, Atrix-C®, and Irix®-C, which offer PEEK, PEEK with a plasma-coated titanium, a structural biologic solution, and a standalone cervical option, respectively.
About Xtant Medical
Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
Tick tock 9 days until launch! Volume increasing :) We should break .01 very soon!
breaking out! broke the pivot point! Should retest moving average at .58!
Profit is profit. Do some research on stock value. Based off of these values we should be trading upward of $1+
$ICLD next leg taking off! Would not be surprised to see the next leg reach .40-.50 IMO True value now after last fins is $1+ get in soon or regret it when we are trading over $1
$ICLD next leg taking off! Would not be surprised to see the next leg reach .40-.50 IMO True value now after last fins is $1+ get in soon or regret it when we are trading over $1
From my experience stocks that go up like this and HOLD gains will continue moving upward! Would not be shocked to see .35-.40+ EOD
$ICLD .20 is breaking out! End of the day rush to .50+ New fins suggest this is now worth upward of $1+ Next leg up now starting!
$ICLD .20 is breaking out! End of the day rush to .50+ New fins suggest this is now worth upward of $1+ Next leg up now starting!
$ICLD .20 is breaking out! End of the day rush to .50+ New fins suggest this is now worth upward of $1+ Next leg up now starting!
Can you feel it? This isn't going down!
End of the day next leg run coming. No one is selling!
this is getting ready to burst upward! :D
This can easily see $1 short term
Looks like sitting a new base at .20 before the next jump IMO
less than 10 days!
Selling is obviously finished!
FINANCIALS JUST RELEASED ON $KOSK!
https://backend.otcmarkets.com/otcapi/company/financial-report/193486/content
FINANCIALS JUST RELEASED ON $KOSK!
https://backend.otcmarkets.com/otcapi/company/financial-report/193486/content
FINANCIALS JUST RELEASED ON $KOSK!
https://backend.otcmarkets.com/otcapi/company/financial-report/193486/content
Amazing to see no more selling. I would say we are at the bottom! :D
Tick tock we are closer to explosion. Ton of accumulation at these levels
16 days now! :D
Nice to see a green finish! With fins this week and launch in 17 days we should break .01+ soon!
$KOSK .0089 Most affordable and most potential canibas stock trading currently! Get in at these levels! This has a very bright future tapping in a untapped part of the sector!
$KOSK .0089 Most affordable and most potential canibas stock trading currently! Get in at these levels! This has a very bright future tapping in a untapped part of the sector!
$KOSK .0089 HUGE NEWS COMING! FINS THIS WEEK AND LAUNCH OF NEW SITE IN THE HEMP INDUSTRY!
$KOSK .0089 HUGE NEWS COMING! FINS THIS WEEK AND LAUNCH OF NEW SITE IN THE HEMP INDUSTRY!
Also why is this down almost 70% since the r/s?
I just fail to understand why this has seen no releases or news since November....